Phase 3 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 18 or older
- People with prostate cancer that has not spread to other parts of the body
- People with prostate cancer that has not spread but where a specific blood marker (PSA) has risen again after previous treatment
- People for whom a doctor has planned radiation therapy to the pelvis (using photon or proton beams), with or without an internal radiation treatment called brachytherapy, aimed at curing the cancer
- People for whom a doctor has planned a combination hormone-blocking treatment (called androgen deprivation therapy, or ADT) together with an additional medication and prednisone, for up to 24 months
Who may not be able to join:
- People with prostate cancer that has spread to other parts of the body and that requires long-term hormone-blocking treatment or chemotherapy
- People who have previously had hormone-blocking therapy (androgen deprivation therapy) for prostate cancer
- People who have previously received chemotherapy, immunotherapy, or radiation therapy
- People with a history of heart bypass surgery or a procedure to open blocked heart arteries (such as a stent or balloon procedure)
- People who have a cardiac pacemaker or a defibrillator device
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sagar A Patel, MD, Emory University Hospital/Winship Cancer Institute
Phone: 404-686-6856
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of ambulatory systolic blood pressure (BP) > 140 or diastolic > 90 (measurement on 2 separate days); Need for new or escalated anti-hypertensive medication; Incidence of moderate-to-severe atherosclerosis of major coronary vessels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.